The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khramilin V.N.

Pirogov Russian National Research Medical University

Davydov O.S.

Research Institute of General Pathology and Pathophysiology

Painful diabetic polyneuropathy: evidence-based diagnosis and treatment

Authors:

Khramilin V.N., Davydov O.S.

More about the authors

Journal: Russian Journal of Pain. 2021;19(4): 44‑59

DOI: 10.17116/pain20211904144

Read: 29973 times

Download PDF (RU)
Contact the author
Table of contents

PAINFUL DIABETIC POLYNEUROPATHY: EVIDENCE-BASED DIAGNOSIS AND TREATMENT
PAINFUL DIABETIC POLYNEUROPATHY: EVIDENCE-BASED DIAGNOSIS AND TREATMENT

To cite this article:

Khramilin VN, Davydov OS. Painful diabetic polyneuropathy: evidence-based diagnosis and treatment. Russian Journal of Pain. 2021;19(4):44‑59. (In Russ.)
https://doi.org/10.17116/pain20211904144

Подписка 2025 Российский журнал боли (Russian Journal of Pain)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Restoration of spermatogenesis suppressed by the use of testosterone, antiestrogen therapy in men with type 2 diabetes mellitus. Russian Journal of Human Reproduction. 2024;(6):156-160
Diabetic reti­nopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Features of comprehensive treatment in a patient with complicated type 2 diabetes mellitus: A clinical case. Piro­gov Russian Journal of Surgery. 2025;(6):128-132
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Cere­brovascular disease in clinical practice. Reso­lution of the Expert Council of the Russian Scientific Medi­cal Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111
Abstract:

OBJECTIVE

To analyze the modern methods of diagnosis and treatment of diabetic polyneuropathy (DPN).

MATERIAL AND METHODS

We searched and analyzed clinical studies, meta-analyses, systematic reviews and guidelines for the diagnosis and treatment of painful DPN. Searching included MEDLINE, ELibrary, PubMed, Web of Science, Google Scholar and Clinical key databases over 20 years. Manuscripts with historical interest were also included.

RESULTS

There were 181 manuscripts. DPN can develop not only in diabetes, but also in patients with prediabetes that expands the indications for screening. Primary diagnosis of DPN implies analysis of anamnesis, complaints, temperature and/or pain sensitivity, vibration and tactile sensitivity. This diagnosis is sufficient for most patients. If differential diagnosis is necessary in complex cases, one can use ENMG, confocal microscopy, assessment of epidermal density of nerve endings and quantitative sensory tests. TCA (Amitriptyline), duloxetine, pregabalin, gabapentin and thioctic acid are recommended for painful DPN. The choice of drugs is based on patient risk profile and potential adverse reactions. Evaluation of efficacy and safety of painful DPN treatment is required. Ineffective therapy requires replacement of drugs and/or combination of medications.

CONCLUSION

The use of the proposed algorithms will make it possible to objectify the diagnosis and improve the quality of medical care in patients with DPN.

Keywords:

diabetes mellitus
diabetic polyneuropathy
diagnosis of diabetic polyneuropathy
treatment of painful diabetic polyneuropathy

Authors:

Khramilin V.N.

Pirogov Russian National Research Medical University

Davydov O.S.

Research Institute of General Pathology and Pathophysiology

Received:

05.10.2021

Accepted:

06.10.2021

Close metadata

References:

  1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15(6): 508-514. https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L "> 3.0.CO;2-L" target="_blank">https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L
  2. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic care, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-93.  https://doi.org/10.2337/dc10-1303
  3. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 28 fevralya 2019 g. №103n «Ob utverzhdenii poryadka i srokov razrabotki klinicheskikh rekomendatsij, ikh peresmotra, tipovoj formy klinicheskikh rekomendatsij i trebovanij k ikh strukture, sostavu i nauchnoj obosnovannosti vklyuchaemoj v klinicheskie rekomendatsii informatsii». Prilozhenie №2 k Trebovaniyam k strukture klinicheskikh rekomendatsij, sostavu i nauchnoj obosnovannosti vklyuchaemoj v klinicheskie rekomendatsii informatsii, utverzhdennym Prikazom Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 28 fevralya 2019 g. №103n (s izmeneniyami ot 23 iyunya 2020 g.). (In Russ.).
  4. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015;12(1-2):48-62.  https://doi.org/10.1900/RDS.2015.12.48
  5. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-350.  https://doi.org/10.1056/NEJMoa032782
  6. Galstyan GR, Starostina EG, Yakhno NN, et al. Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. Diabetes Mellitus. 2019;22(4):305-327. (In Russ.). https://doi.org/10.14341/DM9625
  7. Biessels GJ, Bril V, Calcutt NA, et al. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst. 2014;19(2):77-87.  https://doi.org/10.1111/jns5.12072
  8. O’Brien PD, Hinder LM, Sakowski SA, Feldman EL. ER stress in diabetic peripheral neuropathy: A new therapeutic target. Antioxid Redox Signal. 2014;21(4):621-633.  https://doi.org/10.1089/ars.2013.5807
  9. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573-583. Published 2011 Sept 13.  https://doi.org/10.1038/nrneurol.2011.137
  10. Zenker J, Ziegler D, Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36(8):439-449.  https://doi.org/10.1016/j.tins.2013.04.008
  11. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the Federal diabetes registry. Diabetes Mellitus. 2017;20(1):13-41. (In Russ.). https://doi.org/10.14341/DM8664
  12. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993; 36(2):150-154.  https://doi.org/10.1007/BF00400697
  13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998; 352(9131):837-853. 
  14. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Curr Diab Rep. 2014;14(9):528.  https://doi.org/10.1007/s11892-014-0528-7
  15. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.  https://doi.org/10.2337/dc16-2042
  16. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33(5):1090-1096. https://doi.org/10.2337/dc09-1941
  17. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456-1461. https://doi.org/10.2337/diab.38.11.1456
  18. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):31-38.  https://doi.org/10.2337/dc13-2114
  19. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996; 39(11):1377-1384. https://doi.org/10.1007/s001250050586
  20. Smith AG, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84.  https://doi.org/10.1212/01.CON.0000411568.34085.3e
  21. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24(8):1448-1453. https://doi.org/10.2337/diacare.24.8.1448
  22. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, Ponirakis G, Fadavi H, Boulton AJ, Tavakoli M, Malik RA. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014;37(9):2643-2646. Epub 2014 June 26.  https://doi.org/10.2337/dc14-0279.
  23. Bongaerts BWC, Rathmann W, Heier M, Kowall B, Herder C, Stöckl D, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36(5):1141-1146. https://doi.org/10.2337/dc12-0744
  24. Im S, Kim SR, Park JH, Kim YS, Park GY. Assessment of the medial dorsal cutaneous, dorsal sural, and medial plantar nerves in impaired glucose tolerance and diabetic patients with normal sural and superficial peroneal nerve responses. Diabetes Care. 2012;35(4):834-839.  https://doi.org/10.2337/dc11-1001
  25. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31(3):464-469.  https://doi.org/10.2337/dc07-1796
  26. Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620-628.  https://doi.org/10.1002/dmrr.1226
  27. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473.  https://doi.org/10.1007/s11910-014-0473-5
  28. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43-52.  https://doi.org/10.1093/brain/awu307
  29. Gibbons CH. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep. 2017;17(12):127. Published 2017 Oct 24.  https://doi.org/10.1007/s11892-017-0960-6
  30. Pozzessere G, Rossi P, Gabriele A, et al. Early detection of small-fiber neuropathy in diabetes: a laser-induced pain somatosensory-evoked potentials and pupillometric study. Diabetes Care. 2002;25(12):2355-2358. https://doi.org/10.2337/diacare.25.12.2355
  31. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60(1):108-111.  https://doi.org/10.1212/wnl.60.1.108
  32. Davydov OS, Yakhno NN, Kukushkin ML, Churyukanov MV, et al. Neuropathic pain: clinical guidelines on the diagnostics and treatment from the Russian Association for the Studying of Pain. Russian Journal of Pain. 2018;4(58):5-41. (In Russ.). https://doi.org/10.25731/RASP.2018.04.025
  33. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-638.  https://doi.org/10.1002/dmrr.1225
  34. Malik RA, Veves A, Tesfaye S, et al. Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev. 2011;27(7):678‐684.  https://doi.org/10.1002/dmrr.1222
  35. Salvotelli L, Stoico V, Perrone F, et al. Prevalence of neuropathy in type 2 diabetic patients and its association with other diabetes complications: The Verona Diabetic Foot Screening Program. J Diabetes Complications. 2015;29(8):1066-1070. https://doi.org/10.1016/j.jdiacomp.2015.06.014
  36. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care. 1994;17(11):1281-1289. https://doi.org/10.2337/diacare.17.11.1281
  37. Dedov II, Shestakova MV, Mayorov AYu, Shamkhalova MSh et al. Diabetes mellitus type 1 in adults. Diabetes Mellitus. 2020;23(1S):42-114. (In Russ.). https://doi.org/10.14341/DM12505
  38. Boulton AJM, Vileikyte L. Diagnosis and Staging. In: Painful Diabetic Neuropathy in Clinical Practice. London: Springer. 2011:23-39. First Online: 16 April 2011. https://doi.org/10.1007/978-0-85729-488-3_3
  39. Ziegler D, Keller J, Maier C, Pannek J. DDG Praxisempfehlungen. Diabetische Neuropathie. Diabetologie. 2017;12(suppl 2):S101-S114. (In German).
  40. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(7):1912-1925. https://doi.org/10.1093/brain/awn093
  41. Kallinikos P, Berhanu M, O’Donnell C, Boulton AJM, Efron N, Malik RA. Corneal Nerve Tortuosity in Diabetic Patients with Neuropathy. Investig Opthalmology Vis Sci. 2004;45(2):418-422.  https://doi.org/10.1167/iovs.03-0637
  42. Dedov II, Shestakova MV, Mayorov AYu et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(2S):4-102. (In Russ.). https://doi.org/10.14341/DM12507
  43. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45-56.  https://doi.org/10.1016/0304-3959(83)90126-4
  44. Von Korff M, Jensen MP, Karoly P. Assessing global pain severity by self-report in clinical and health services research. Spine (Phila Pa 1976). 2000; 25(24):3140-3151. https://doi.org/10.1097/00007632-200012150-00009
  45. Khramilin VN, Strokov IA, Davydov OS, Churyukanov MV. Diagnosis of diabetic polyneuropathy in primary care. Russian Journal of Pain. 2021;19(2): 47-59. (In Russ.). https://doi.org/10.17116/pain20211902147
  46. Diadetes Control and Complication Trial (DCCT) Research Group. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol. 1995;38(6):869-880.  https://doi.org/10.1002/ana.410380607
  47. Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes Mellitus. 2019;22(1S1): 1-144. (In Russ.). https://doi.org/10.14341/DM221S1
  48. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019; 42(suppl 1):124-138.  https://doi.org/10.2337/dc19-S011
  49. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19(10):870-873.  https://doi.org/10.1046/j.1464-5491.2002.00801.x
  50. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294-1299. https://doi.org/10.2337/dc06-0224
  51. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458-1486. https://doi.org/10.2337/diacare.27.6.1458
  52. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.  https://doi.org/10.1016/S1474-4422(14)70251-0
  53. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(7):CD008242. Published 2015 July 06.  https://doi.org/10.1002/14651858.CD008242.pub3
  54. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076. Published 2009 July 08.  https://doi.org/10.1002/14651858.CD007076.pub2
  55. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015; 2015(8):CD011091. Published 2015 Aug 23.  https://doi.org/10.1002/14651858.CD011091.pub2
  56. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014; (1):CD007115. Published 2014 Jan 03.  https://doi.org/10.1002/14651858.CD007115.pub3
  57. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. Published 2017 June 09.  https://doi.org/10.1002/14651858.CD007938.pub4
  58. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia — an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;2013(11):CD010567. Published 2013 Nov 11.  https://doi.org/10.1002/14651858.CD010567.pub2
  59. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1): CD007076. Published 2019 Jan 23.  https://doi.org/10.1002/14651858.CD007076.pub3
  60. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD007393. Published 2017 Jan 13.  https://doi.org/10.1002/14651858.CD007393.pub4
  61. Van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. Clin Ther. 2017;39(4):787-803.e18.  https://doi.org/10.1016/j.clinthera.2017.02.010
  62. Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6(6):CD003726. Published 2017 June 15.  https://doi.org/10.1002/14651858.CD003726.pub4
  63. Cooper TE, Chen J, Wiffen PJ, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5(5):CD011669. Published 2017 May 22.  https://doi.org/10.1002/14651858.CD011669.pub2
  64. Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;7(7):CD010692. Published 2016 July 28.  https://doi.org/10.1002/14651858.CD010692.pub3
  65. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in Neurology. 2011;77(6):603. Dosage error in article text]. Neurology. 2011;76(20):1758-1765. https://doi.org/10.1212/WNL.0b013e3182166ebe
  66. Ziegler D, Keller J, Maier C, Pannek J. DDG Praxisempfehlungen. Diabetische Neuropathie. Diabetologie. 2019;14(suppl 2):243-257. (In German). https://doi.org/10.1055/a-0899-0129
  67. Ilias W, Kress H-G, Abrahamian H, Gustorff B, Kress M, Lampl C, Likar R, Quasthoff S, Schernthaner G, Toplak H, Ziegler D. Konsensus-statement der österreichischen schmerzgesellschaft. Empfehlungen zur Schmerztherapie bei Peripherer Diabetischer Polyneuropathie. Zeitschrift der Österreichischen Schmerzgesellschaft. 2010;4b. ISSN 2076-7625.
  68. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, Lanteri-Minet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325-352.  https://doi.org/10.1016/j.neurol.2020.01.361.
  69. State Register of Medicines. Accessed June 30, 2021. https://grls.rosminzdrav.ru
  70. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31(7):1448-1454. https://doi.org/10.2337/dc07-2105
  71. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis [published correction appears in Ann Intern Med. 2015;162(8):600] [published correction appears in Ann Intern Med. 2015;162(10):739]. Ann Intern Med. 2014;161(9):639-649.  https://doi.org/10.7326/M14-0511
  72. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115(3):254-263.  https://doi.org/10.1016/j.pain.2005.02.032
  73. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628-638.  https://doi.org/10.1016/j.pain.2004.05.001
  74. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain. 2005;6(4):253-260.  https://doi.org/10.1016/j.jpain.2004.12.007
  75. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” — a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616-2625. https://doi.org/10.1016/j.pain.2013.05.043
  76. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain. 2007;8:118-126. 
  77. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6. Published 2009 Feb 10.  https://doi.org/10.1186/1471-2377-9-6
  78. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab Res Rev. 2005;21(3):231-240.  https://doi.org/10.1002/dmrr.552
  79. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-1836. https://doi.org/10.1001/jama.280.21.1831
  80. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003; 25(1):81-104.  https://doi.org/10.1016/s0149-2918(03)90011-7
  81. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage. 2000;20(4):280-285.  https://doi.org/10.1016/s0885-3924(00)00181-0
  82. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132(3):237-251.  https://doi.org/10.1016/j.pain.2007.08.033
  83. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999; 159(16):1931-1937. https://doi.org/10.1001/archinte.159.16.1931
  84. Khasbage S, Shukla R, Sharma P, Singh S. A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy. J Diabetes. 2021; 13(7):532-541.  https://doi.org/10.1111/1753-0407.13148
  85. Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy. Drug Des Devel Ther. 2019;13:1985-1992. https://doi.org/10.2147/DDDT.S185995
  86. Jones RC 3rd, Lawson E, Backonja M. Managing Neuropathic Pain. Med Clin North Am. 2016;100(1):151-167.  https://doi.org/10.1016/j.mcna.2015.08.009
  87. Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. Int J Mol Sci. 2017;18(11):2483. Published 2017 Nov 21.  https://doi.org/10.3390/ijms18112483
  88. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454. Published 2007 Oct 17.  https://doi.org/10.1002/14651858.CD005454.pub2
  89. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589-596.  https://doi.org/10.1212/wnl.37.4.589
  90. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250-1256. https://doi.org/10.1056/NEJM199205073261904
  91. Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther. 1995;12(2):111-120. 
  92. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012; 35(12):2451-2458. https://doi.org/10.2337/dc12-0656
  93. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA. 1993;269:2673-2675.
  94. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75(3):234-241.  https://doi.org/10.1016/j.clpt.2003.09.019
  95. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45(1):17-28.  https://doi.org/10.1176/appi.psy.45.1.17
  96. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-118.  https://doi.org/10.1016/j.pain.2005.03.029
  97. Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67(8):1411-1420. https://doi.org/10.1212/01.wnl.0000240225.04000.1a
  98. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7(5):373-385.  https://doi.org/10.1111/j.1526-4637.2006.00207.x
  99. Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the Efficacy of Duloxetine and Pregabalin in Pain Relief Associated with Diabetic Neuropathy. Cureus. 2019;11(7):e5293. https://doi.org/10.7759/cureus.5293
  100. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [published correction appears in Pain. 2005;113(1-2):248]. Pain. 2004;110(3):697-706.  https://doi.org/10.1016/j.pain.2004.05.010
  101. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60(8):1284-1289. https://doi.org/10.1212/01.wnl.0000058749.49264.bd
  102. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167-184.  https://doi.org/10.1111/papr.12054
  103. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16(12):1040-1043. https://doi.org/10.1046/j.1464-5491.1999.00190.x
  104. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-2370. https://doi.org/10.2337/dc06-1216
  105. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425-1433. https://doi.org/10.1007/BF00400603
  106. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114-121.  https://doi.org/10.1111/j.1464-5491.2004.01109.x
  107. Papanas N. & Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin. Pharmacother. 2014;15(18):2721-2731. https://doi.org/10.1517/14656566.2014.972935
  108. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167(4):465-471.  https://doi.org/10.1530/EJE-12-0555
  109. McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377-385.  https://doi.org/10.2147/TCRM.S11325
  110. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012: 456279. https://doi.org/10.1155/2012/456279
  111. Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016; 33(11):1466-1476. https://doi.org/10.1111/dme.13083
  112. Nguyen N, Takemoto JK. A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy. J Pharm Pharm Sci. 2018;21(1s): 177s-191s. https://doi.org/10.18433/jpps30100
  113. El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531-1534. https://doi.org/10.2174/1871530320666200506081407
  114. Amato Nesbit S, Sharma R, Waldfogel JM, Zhang A, Bennett WL, Yeh HC, Chelladurai Y, Feldman D, Robinson KA, Dy SM. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2019;35(1):15-25.  https://doi.org/10.1080/03007995.2018.1497958
  115. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials. International Journal of Endocrinology. 2012;2012:456279. https://doi.org/10.1155/2012/456279
  116. Garcia-Alcala H, et al. Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. Journal of Diabetes Research. 2015; 2015:189857. Published online 2015 Aug 04.  https://doi.org/10.1155/2015/189857
  117. Ziegler D, Papanas N, Schnell O, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12(4):464-475.  https://doi.org/10.1111/jdi.13401
  118. Baron R, Mahn F. Topische Therapieformen bei peripheren neuropathischen Schmerzen: Wirkmechanismus und Indikationen [Types of topical treatment for peripheral neuropathic pain: Mechanism of action and indications]. Schmerz. 2010;24(4):317-325. (In German). https://doi.org/10.1007/s00482-010-0939-6
  119. Sommer C, Cruccu G. Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence. J Pain Symptom Manage. 2017;53(3):614-629.  https://doi.org/10.1016/j.jpainsymman.2016.09.015
  120. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society. Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574. https://doi.org/10.1210/jc.2019-00198
  121. Pickering G, Marcoux M, Chapiro S, David L, Rat P, Michel M, et al. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33:575-583.  https://doi.org/10.1007/s40266-016-0389-7
  122. Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23(1):147-161.  https://doi.org/10.1185/030079906X162674
  123. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842-1846. https://doi.org/10.1212/wnl.50.6.1842
  124. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000;14(2):65-70.  https://doi.org/10.1016/s1056-8727(00)00060-x
  125. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151-162.  https://doi.org/10.1185/03007995.2010.537589
  126. Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302-2309. https://doi.org/10.2337/dc13-2291
  127. Holbech JV, Jung A, Jonsson T, Wanning M, Bredahl C, Bach FW. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017;10:1467-1475. Published 2017 June 26.  https://doi.org/10.2147/JPR.S138099
  128. Eisenberg E, Suzan E. Drug combinations in the treatment of neuropathic pain. Curr Pain Headache Rep. 2014;18(12):463.  https://doi.org/10.1007/s11916-014-0463-y
  129. Schug SA. Drug synergy and therapeutic combinations. In: Neuropathic pain: causes, management, and understanding. Toth C, Moulin DE, eds. Cambridge University Press. 2013;290-298. Published online 2013 December 05.  https://doi.org/10.1017/CBO9781139152211.025
  130. Jolivalt CG, Mizisin LM, Nelson A, et al. B vitamins alleviate indices of neuropathic pain in diabetic rats. Eur J Pharmacol. 2009;612(1-3):41-47.  https://doi.org/10.1016/j.ejphar.2009.04.028
  131. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, Co HU, Bautista MR, Roxas AA. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;(3):CD004573. https://doi.org/10.1002/14651858.CD004573.pub3
  132. Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr. 2009;60(suppl 5):71-76.  https://doi.org/10.1080/09637480802406153
  133. Onysko M, Legerski P, Potthoff J, Erlandson M. Targeting neuropathic pain: consider these alternatives. J Fam Pract. 2015;64(8):470-475. 
  134. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) [published correction appears in Int J Clin Pharmacol Ther. 2005;43(6):304]. Int J Clin Pharmacol Ther. 2005;43(2):71-77.  https://doi.org/10.5414/cpp43071
  135. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600-605.  https://doi.org/10.1055/s-2008-1065351
  136. Medina-Santillán R, Morales-Franco G, Espinoza-Raya J, Granados-Soto V, Reyes-García G. Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. Proc West Pharmacol Soc. 2004;47:109-112. 
  137. Jacobs A, Cheng D. Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy. Journal of Diabetes Mellitus. 2013;3:134-138.  https://doi.org/10.4236/jdm.2013.33020
  138. Khramilin VN, Andreeva VA, Demidova IYu. Combined therapy of diabetic polyneuropathy: results of pilot study. Pharmateca. 2014;16(289):48-53. (In Russ.).
  139. Mimenza Alvarado A, Aguilar Navarro S. Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. J Diabetes Res. 2016;2016:4078695. https://doi.org/10.1155/2016/4078695
  140. Mantha S, Thisted R, Foss J, Ellis JE, Roizen MF. A proposal to use confidence intervals for visual analog scale data for pain measurement to determine clinical significance. Anesth Analg. 1993;77(5):1041-1047. Erratum in: Anesth Analg. 1994;78(5):1035. PMID: 8214704. https://doi.org/10.1213/00000539-199311000-00029
  141. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.  https://doi.org/10.1016/s0304-3959(01)00349-9
  142. Vinik AI, Casellini CM. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes Metab Syndr Obes. 2013;6:57-78.  https://doi.org/10.2147/DMSO.S24825
  143. Bates D, Carsten Schultheis B, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, Levy RM, Hunter CW. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Medicine. 2019;20:2-12.  https://doi.org/10.1093/pm/pnz075
  144. Huizinga MM, Peltier A. Painful diabetic neuropathy: A management-centered review. Clinical Diabetes. 2007;25(1):6-15.  https://doi.org/10.2337/diaclin.25.1.6
  145. Gibson W, Wand BM, O’Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;9(9):CD011976. Published 2017 Sept 14.  https://doi.org/10.1002/14651858.CD011976.pub2
  146. Ju ZY, Wang K, Cui HS, et al. Acupuncture for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;12(12):CD012057. Published 2017 Dec 02.  https://doi.org/10.1002/14651858.CD012057.pub2
  147. Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, Yeh HC, Chelladurai Y, Feldman D, Wilson LM, Robinson KA. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy. [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Mar. Report No. 17-EHC005-EF. 
  148. Nathan HJ, Poulin P, Wozny D, Taljaard M, Smyth C, Gilron I, et al. Randomized trial of the effect of mindfulness-based stress reduction on pain-related disability, pain intensity, health-related quality of life, and A1C in patients with painful diabetic peripheral neuropathy. Clin Diabetes Publ Am Diabetes Assoc. 2017;35:294-304.  https://doi.org/10.2337/cd17-0077
  149. Aamir A, Girach A, Sarrigiannis PG, et al. Repetitive Magnetic Stimulation for the Management of Peripheral Neuropathic Pain: A Systematic Review. Adv Ther. 2020;37(3):998-1012. https://doi.org/10.1007/s12325-020-01231-2
  150. Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation. 2009;90(7):1102-1109. https://doi.org/10.1016/j.apmr.2009.01.019
  151. Wróbel MP, Szymborska-Kajanek A, Wystrychowski G, Biniszkiewicz T, Sieroń-Stołtny K, Sieroń A, Pierzchała K, Grzeszczak W, Strojek K. Impact of low frequency pulsed magnetic fields on pain intensity, quality of life and sleep disturbances in patients with painful diabetic polyneuropathy. Diabetes & Metabolism. 2008;34(4 Pt 1):349-354.  https://doi.org/10.1016/j.diabet.2008.02.003
  152. Magnetic therapy in medical rehabilitation and preventive programs: clinical guidelines. M. 2015:47. 
  153. Gupta M, Knezevic NN, Abd-Elsayed A, Ray M, Patel K, Chowdhury B. Treatment of Painful Diabetic Neuropathy — A Narrative Review of Pharmacological and Interventional Approaches. Biomedicines. 2021;9(5):573.  https://doi.org/10.3390/biomedicines9050573
  154. Ferini-Strambi L. Neuropathic Pain and Sleep: A Review. Pain Ther. 2017;6(suppl 1):19-23.  https://doi.org/10.1007/s40122-017-0089-y
  155. Vileikyte L, Peyrot M, Gonzalez JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009;52(7):1265-1273. https://doi.org/10.1007/s00125-009-1363-2
  156. Haanpää ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 suppl):S15-S25.  https://doi.org/10.4065/mcp.2009.0645
  157. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35(5):612-623.  https://doi.org/10.1016/j.clinthera.2013.03.008
  158. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324-1334. https://doi.org/10.1056/NEJMoa042580
  159. Agathos E, Tentolouris A, Eleftheriadou I, Katsaouni P, Nemtzas I, Petrou A, Papanikolaou C, Tentolouris N. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018;46(5):1779-1790. https://doi.org/10.1177/0300060518756540
  160. LeRoith D, Jan Biessels G, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, Hirsch IB, McDonnell ME, Molitch ME, Hassan Murad M, Sinclair AJ. Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520-1574. https://doi.org/10.1210/jc.2019-00198
  161. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain. 2007;23(3):251-258.  https://doi.org/10.1097/AJP.0b013e31802f67dd
  162. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2-8.  https://doi.org/10.1016/s0002-9343(99)00301-0
  163. Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709-2718. https://doi.org/10.2147/DDDT.S142630
  164. Pham PC, Khaing K, Sievers TM, et al. 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J. 2017;10(5):688-697.  https://doi.org/10.1093/ckj/sfx080
  165. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J Am Soc Nephrol. 2018;29(7):1970-1978. https://doi.org/10.1681/ASN.2018010096
  166. Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27(2):188-204.  https://doi.org/10.1111/sdi.12196
  167. Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):32-69.  https://doi.org/10.1161/CIR.0000000000000426
  168. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.  https://doi.org/10.1056/NEJM199309303291401
  169. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: A randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996;45(12):1508-1513. https://doi.org/10.1016/s0026-0495(96)90180-8
  170. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-534.  https://doi.org/10.1016/S1474-4422(12)70065-0
  171. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [published correction appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet. 2010;376(9739):419-430.  https://doi.org/10.1016/S0140-6736(10)60576-4
  172. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.  https://doi.org/10.1016/0168-8227(95)01064-k
  173. Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: The ADDITION-Denmark study. Diabetes Care. 2011;34(10):2244-2249. https://doi.org/10.2337/dc11-0903
  174. Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2013;56(1):101-108.  https://doi.org/10.1007/s00125-012-2744-5
  175. Singleton JR, Smith AG, Marcus RL. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep. 2015;15(12):120.  https://doi.org/10.1007/s11892-015-0682-6
  176. Singleton JR, Marcus RL, Jackson JE, K Lessard M, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014;1(10):844-849.  https://doi.org/10.1002/acn3.125
  177. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216-223.  https://doi.org/10.1016/j.jdiacomp.2005.07.005
  178. Gu Y, Dennis SM, Kiernan MC, Harmer AR. Aerobic exercise training may improve nerve function in type 2 diabetes and pre-diabetes: A systematic review. Diabetes Metab Res Rev. 2019;35(2):e3099. https://doi.org/10.1002/dmrr.3099
  179. Gholami F, Nikookheslat S, Salekzamani Y, Boule N, Jafari A. Effect of aerobic training on nerve conduction in men with type 2 diabetes and peripheral neuropathy: A randomized controlled trial. Neurophysiol Clin. 2018; 48(4):195-202.  https://doi.org/10.1016/j.neucli.2018.03.001
  180. Yoo M, Sharma N, Pasnoor M, Kluding PM. Painful Diabetic Peripheral Neuropathy: Presentations, Mechanisms, and Exercise Therapy. J Diabetes Metab. 2013;(suppl 10):005.  https://doi.org/10.4172/2155-6156.S10-005
  181. Miller JD, Carter E, Shih J, Giovinco NA, Boulton AJ, Mills JL, Armstrong DG. How to do a 3-minute diabetic foot exam. J Fam Pract. 2014; 63(11):646-656. Erratum in: J Fam Pract. 2015;64(8):452. PMID: 25362495.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.